Millennium Pharmaceuticals Limited

Cytel Corporation

Athena Neurosciences, Inc.

S Tarran Jones

Walter Newman

Theresa O'Keefe

Gregory J LaRosa

Christopher Horvath

Siobhan H O'Brien

Mary M Bendig

Robert J Bayer

Paul D Ponath

Michael Kriegler

James C Paulson

Carl F Perez

José W Saldanha

Douglas J Ringler

Margaret J Polley

Michael Nunn

Jose William Saldanha

Ted A Yednock

Olivier J Leger

Robert W Chestnut

José Saldanha

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Humanized anti-CCR2 antibodies and methods of use therefor

The present invention relates to isolated nucleic acids encoding humanized immunoglobulins having binding specificity for &#x3b1;4&#x3b2;7 integrin, isolated nucleic acids encoding a humanized immunoglobulin heavy chain and isolated nucleic acids encoding a humanized light chain having binding specificity for &#x3b1;4&#x3b2;7 integrin. The invention also relates to expression vectors and host cells comprising a nucleotide sequence which encodes a humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for &#x3b1;4&#x3b2;7. The invention further relates to methods of preparing a humanized immunoglobulin, humanized immunoglobulin heavy chain and humanized immunoglobulin light chain that has binding specificity for &#x3b1;4&#x3b2;7 integrin.

Humanized immunoglobulin reactive with &#x3b1;4&#x3b2;7 integrin

The present invention relates to humanized immunoglobulins having binding specificity for &#x3b1;4&#x3b2;7 integrin, comprising an antigen binding region of nonhuman origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region). In one embodiment, the humanized immunoglobulin can compete with murine Act-1 for binding to human &#x3b1;4&#x3b2;7 integrin. In a preferred embodiment, the antigen binding region of the humanized immunoglobulin comprises each of the complementarity determining regions of the light and heavy chains of the murine Act-1 antibody.

Recombinant anti-CCR2 antibodies and methods of use therefor

The present invention relates to compositions and methods for treating inflammation and other pathological conditions using novel blocking P-selectin antibodies that inhibit adhesion of leukocytes to activated platelets and/or to activated vascular endothelium in vivo. Both murine and humanized antibodies are provided.

Method for detecting the presence of P-selectin

The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.

Humanized antibodies against leukocyte adhesion molecule VLA-4

Antibodies to P-selectin and their uses

Growing community of inventors

Radlett, United Kingdom

S Tarran Jones